Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPRT1 | P00492 | 4/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.46 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.41 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.40 |
| ▸ | CYP1B1 | Q16678 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.39 |
| ▸ | MAPT | P10636 | 2/20 | 0.39 |
| ▸ | LCK | P06239 | 1/20 | 0.39 |
| ▸ | FYN | P06241 | 1/20 | 0.39 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.39 |
| ▸ | ACHE | P22303 | 1/20 | 0.39 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.39 |
| ▸ | AHR | P35869 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 2/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL349078 | 0.90 | HSD17B10 (0.46) | HPRT1ALDH1A1HSD17B10TDP1CYP2A6 | |
| SCHEMBL30579631 | 0.78 | HPRT1 (0.61) | HPRT1ALDH1A1HSD17B10TDP1CYP2A6 | |
| SCHEMBL7345934 | 0.76 | HPRT1 (0.58) | HPRT1ALDH1A1HSD17B10TDP1CYP2A6 | |
| SCHEMBL30446008 | 0.76 | HPRT1 (0.52) | HPRT1ALDH1A1HSD17B10TDP1CYP2A6 | |
| SCHEMBL1445153 | 0.76 | HPRT1 (0.52) | HPRT1ALDH1A1HSD17B10TDP1CYP2A6 | |
| SCHEMBL30541938 | 0.76 | HPRT1 (0.52) | HPRT1ALDH1A1HSD17B10TDP1CYP2A6 | |
| SCHEMBL31497107 | 0.76 | HPRT1 (0.52) | HPRT1ALDH1A1HSD17B10TDP1CYP2A6 | |
| SCHEMBL159626 | 0.76 | HPRT1 (0.52) | HPRT1ALDH1A1HSD17B10TDP1CYP2A6 | |
| SCHEMBL12475251 | 0.76 | HPRT1 (0.52) | HPRT1ALDH1A1HSD17B10TDP1CYP2A6 | |
| SCHEMBL30516909 | 0.76 | HPRT1 (0.52) | HPRT1ALDH1A1HSD17B10TDP1CYP2A6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 111 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170189443-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF DISEASES AND CONDITIONS EMPLOYING ORAL ADMINISTRATION OF SODIUM PENTOSAN POLYSULFATE AND OTHER PENTOSAN POLYSULFATE SALTS | PLATINUM MONTAUR LIFE SCIENCES, LLC AND AS AGENT (KY) | 2017-07-06 | — | — | US | claimed |
| EP-3110427-A1 | COMPOSITIONS OF PENTOSAN POLYSULFATE SALTS FOR ORAL ADMINISTRATION AND METHODS OF USE | Urigen Pharmaceuticals, Inc. (US) | 2017-01-04 | — | — | EP | claimed |
| WO-2015127416-A1 | COMPOSITIONS OF PENTOSAN POLYSULFATE SALTS FOR ORAL ADMINISTRATION AND METHODS OF USE | URIGEN PHARMACEUTICALS, INC. (US) | 2015-08-27 | — | — | WO | claimed |
| US-20100143473-A1 | COMBINATION TREATMENT WITH STRONTIUM FOR THE PROPHYLAXIS AND/OR TREATMENT OF CARTILAGE AND/OR BONE CONDITIONS | OSTEOLOGIX A/S | 2010-06-10 | — | — | US | claimed |
| US-20090035315-A1 | Method of Improving Treatments in Rheumatic and Arthritic Diseases | OSTEOLOGIX A/S (DK) | 2009-02-05 | — | — | US | claimed |
| EP-1758653-A2 | TREATMENTS COMPRISING STRONTIUM FOR RHEUMATIC AND ARTHRITIC DISEASES AND PAIN | Osteologix A/S (DK) | 2007-03-07 | — | — | EP | claimed |
| US-20060275503-A1 | Combination treatment with strontium for the prophylaxis and/or treatment of cartilage and/or bone conditions | NORDIC BONE A/S (DK) | 2006-12-07 | — | — | US | claimed |
| EP-1622630-A2 | STRONTIUM COMBINATIONS FOR THE PROPHYLAXIS/TREATMENT OF CARTILAGE AND/OR BONE CONDITIONS | Osteologix A/S (DK) | 2006-02-08 | — | — | EP | claimed |
| WO-2005123193-A2 | TREATMENTS COMPRISING STRONTIUM FOR RHEUMATIC AND ARTHRITIC DISEASES AND PAIN | OSTEOLOGIX A/S (DK) | 2005-12-29 | — | — | WO | claimed |
| WO-2005123130-A2 | IMPROVED TREATMENTS OF RHEUMATIC AND ARTHRITIC DISEASES COMPRISING COMBINATIONS OF A 5-LIPOXYGENASE INHIBITOR | OSTEOLOGIX A/S (DK) | 2005-12-29 | — | — | WO | claimed |
| WO-2004098618-A2 | STRONTIUM COMBINATIONS FOR PROPHYLAXIS/TREATMENT OF CARTILAGE AND/OR BONE CONDITIONS | OSTEOLOGIX A/S (DK) | 2004-11-18 | — | — | WO | claimed |
| EP-1465619-A1 | SUPPRESSION OF CARTILAGE DEGRADATION VIA THE ESTROGEN RECEPTOR | Nordic Bioscience A/S (DK) | 2004-10-13 | — | — | EP | claimed |
| WO-2003063859-A1 | SUPPRESSION OF CARTILAGE DEGRADATION VIA THE ESTROGEN RECEPTOR | NORDIC BIOSCIENCE A/S (DK) | 2003-08-07 | — | — | WO | claimed |
| US-20230310385-A1 | TREATMENT OF ER-NEGATIVE BREAST CANCER WITH AN PDGF-CC INHIBITOR AND AN ANTI-ESTROGEN | PARACRINE THERAPEUTICS AB (SE) | 2023-10-05 | — | — | US | disclosed |
| EP-3373967-B9 | TREATMENT OF ER-NEGATIVE BREAST CANCER WITH AN PDGF-CC INHIBITOR AND AN ANTI ESTROGEN | PARACRINE THERAPEUTICS AB (SE) | 2023-10-04 | — | — | EP | disclosed |
| EP-3373967-B1 | TREATMENT OF ER-NEGATIVE BREAST CANCER WITH AN PDGF-CC INHIBITOR AND AN ANTI ESTROGEN | PARACRINE THERAPEUTICS AB (SE) | 2023-06-07 | — | — | EP | disclosed |
| US-4894373-A | CLOMIPHEN, ISOMERS AND SALTS | BCM TECHNOLOGIES, INC. (US) | 1990-01-16 | — | — | US | disclosed |
| US-4729999-A | MENOPAUSE, SIDE EFFECT PREVENTION | BCM TECHNOLOGIES (US) | 1988-03-08 | — | — | US | disclosed |
| EP-0063052-B1 | STARTING PITCHES FOR CARBON FIBERS | NIPPON OIL CO. LTD. (JP) | 1986-09-03 | — | — | EP | disclosed |
| EP-0178862-A2 | Antiestrogen therapy for symptoms of estrogen deficiency | BCM Technologies, INC. (US) | 1986-04-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170189443-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF DISEASES AND CONDITIONS EMPLOYING ORAL ADMINISTRATION OF SODIUM PENTOSAN POLYSULFATE AND OTHER PENTOSAN POLYSULFATE SALTS | SI, SLC20A1, SLC20A2 | HPRT1 2455/4885ALDH1A1 3725/4885HSD17B10 1827/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.